UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 208

Sortiert nach

The role of HOX genes in normal hematopoiesis and acute leukemia

Leukemia, 2013-05, Vol.27 (5), p.1000-1008

2013

Volltextzugriff (PDF)

HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer)

British journal of cancer, 2009-02, Vol.100 (3), p.470-475

2009

Volltextzugriff (PDF)

Science in Focus – Oncolytic Viruses: New Multifunctional Immunotherapeutics

Clinical oncology (Royal College of Radiologists (Great Britain)), 2016-10, Vol.28 (10), p.615-618

Pandha, H.S

2016

Volltextzugriff (PDF)

Measles virus causes immunogenic cell death in human melanoma

Gene therapy, 2013-01, Vol.20 (1), p.7-15

2013

Volltextzugriff (PDF)

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

Gene therapy, 2009-05, Vol.16 (5), p.689-699

2009

Volltextzugriff (PDF)

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

Gene therapy, 2008-06, Vol.15 (12), p.911-920

2008

Volltextzugriff (PDF)

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy

Gene therapy, 2017-01, Vol.24 (1), p.21-30

2017

Volltextzugriff (PDF)

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

Annals of oncology, 2018-10, Vol.29 (10), p.2098-2104

2018

Volltextzugriff (PDF)

The biology of the sodium iodide symporter and its potential for targeted gene delivery

Current cancer drug targets, 2010-03, Vol.10 (2), p.242

2010

Volltextzugriff (PDF)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

Cytokine & growth factor reviews, 2010-04, Vol.21 (2), p.91-98

2010

Volltextzugriff (PDF)

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

Gene therapy, 2008-09, Vol.15 (18), p.1257-1270

2008

Volltextzugriff (PDF)

Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study

The Journal of urology, 2007-06, Vol.177 (6), p.2136

2007

Volltextzugriff (PDF)

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer

Gene therapy, 2016-04, Vol.23 (4), p.357-368

2016

Volltextzugriff (PDF)

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy

Gene therapy, 2013-05, Vol.20 (5), p.521-528

2013

Volltextzugriff (PDF)

Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study

British journal of cancer, 2016-10, Vol.115 (9), p.1078-1086

2016

Volltextzugriff (PDF)

Lymphokine‐activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites

International journal of cancer, 2014-03, Vol.134 (5), p.1091-1101

2014

Volltextzugriff (PDF)

Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines

Clinical and experimental immunology, 2007-04, Vol.148 (1), p.127-135

2007

Volltextzugriff (PDF)

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer

Oral oncology, 2013-02, Vol.49 (2), p.108-118

2013

Volltextzugriff (PDF)

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling

Oncogene, 2014-03, Vol.33 (13), p.1700-1712

2014

Volltextzugriff (PDF)

Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy

British journal of cancer, 2009-06, Vol.100 (12), p.1889-1895

2009

Volltextzugriff (PDF)

Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells

Leukemia, 2010-09, Vol.24 (9), p.1555-1565

2010

Volltextzugriff (PDF)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer

British journal of cancer, 2012-01, Vol.106 (3), p.496-507

2012

Volltextzugriff (PDF)

Recent clinical experience with oncolytic viruses

Current pharmaceutical biotechnology, 2012-07, Vol.13 (9), p.1834

2012

Volltextzugriff (PDF)

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Annals of oncology, 2018-10, Vol.29, p.viii732-viii732

2018

Volltextzugriff (PDF)

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

British journal of cancer, 2004-03, Vol.90 (5), p.955-961

2004

Volltextzugriff (PDF)

1 – 25 von 208

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(193)
Mit Volltextzugriff
(172)

Publikationsform

Artikel
(208)

Sprache

Englisch
(208)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The role of HOX genes in normal hematopoiesis and acute leukemia

HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer)

Science in Focus – Oncolytic Viruses: New Multifunctional Immunotherapeutics

Measles virus causes immunogenic cell death in human melanoma

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

The biology of the sodium iodide symporter and its potential for targeted gene delivery

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy

Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study

Lymphokine‐activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites

Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling

Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy

Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer

Recent clinical experience with oncolytic viruses

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

Suchergebnisse filtern